SIM0518 not checked
Jiangsu Simcere Pharmaceutical Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “SIM0518 is an oral, next-generation, highly selective ALK/ROS1 dual inhibitor. Bupropion is a sensitive probe substrate for cytochrome P2B6 SIM0518+Repaglinide”In the company’s words, NCT07912268 on ClinicalTrials.gov
- Main trialPhase 1
- “This is a multicenter, open-label, Phase I study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetic /pharmacodynamic characteristics of SIM0518 in trial participants with ALK-positive or ROS1-positive locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC). The study starts with a dose escalation part (Part 1), followed by a dose expansion part (Part 2). A Drug-Drug Interaction (DDI) study (Part 3) may be conducted after the Recommended Dose of SIM0518 is determined.”In the company’s words, NCT07912268 on ClinicalTrials.gov
Other drugs for ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- CobimetinibRoche · Phase 2/3
- DivarasibRoche · Phase 3
- EntrectinibRoche · Phase 3
Coming up1
- 1 Dec 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | 1 Dec 2028 | Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026